Minnesota to Require Medical Marijuana Retailers to Carry State-Designated ‘High Medical Need’ Products Starting January 1
- Minnesota marijuana businesses serving medical patients must stock a state-designated list of “high medical need” products starting January 1, 2027, as mandated by new legislation.
- The Office of Cannabis Management (OCM) will identify and publicly post this list, including pills, water-soluble cannabinoids, orally dissolvable products, and tinctures, with authority to add more products.
- Medical cannabis retailers are required to carry all listed products and prioritize service to registered patients and caregivers; manufacturers must produce products on the list.
- Regulators have enforcement powers, including penalties and license suspensions, for businesses that fail to provide these products within 24 hours of patient requests, amid a broader 2027 overhaul of Minnesota’s marijuana industry licensing and supply chain.
Minnesota marijuana businesses that serve medical patients will soon be required to stock a state-designated list of “high medical need” products, under changes taking effect January 1, 2027.
Under a law approved by lawmakers earlier this year, the Minnesota Office of Cannabis Management (OCM) must identify and publicly post a list of marijuana products considered to have a high medical need.
Businesses holding a medical cannabis retail endorsement will be required to carry every product identified on the list while also providing priority service to registered patients and caregivers.
The law establishes several products that must be included on the list, including pills; water-soluble cannabinoid products such as granules, powders and sprinkles; orally dissolvable products including lozenges, gum, mints, buccal tablets and sublingual tablets; and tinctures.
OCM may designate additional products beyond those specifically named in the statute.
The requirements are part of a broader restructuring of Minnesota’s medical and recreational marijuana systems that takes effect at the beginning of 2027. The state is moving toward a streamlined supply chain while maintaining separate protections and benefits for registered medical marijuana patients.
According to an OCM summary of the changes, businesses with medical retail endorsements will be required to ensure the availability of high-medical-need products, while manufacturers with medical marijuana endorsements must manufacture products included on the list.
The law also gives regulators enforcement authority if businesses fail to maintain access to the designated products. OCM may issue administrative orders, embargo products, impose civil penalties or suspend or revoke a medical marijuana endorsement.
Specifically, regulators may take action if a retailer fails to make a high-medical-need product available at a retail location within 24 hours of a patient’s request.
Minnesota’s broader 2027 changes will also replace the existing medical cannabis combination business license with a new macrobusiness license and allow additional marijuana businesses to obtain medical cultivation, manufacturing and retail endorsements.